Verastem makes its stand as a RevMed competitor in pancreatic cancer
Verastem Oncology had a big Wednesday morning: it announced new data amid a tense competition for the next-wave KRAS agents, as well as a $250 million raise and the departure of its CEO. The Massachusetts ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.